Skip to main content

Table 1 Analysis of potential maternal factors influencing EBV infection in infants during the first 12 months of life and infants characteristics

From: HIV-exposed infants with EBV infection have a reduced persistence of the immune response to the HBV vaccine

 

EBV + infants (n = 49)

EBV− infants (n = 66)

P value

Maternal age (years)

28.0 (23.0–30.5)

26.5 (24.0–31.3)

0.847

Weight (kg)

59.5 (54.9–66.8)

55.5 (51.2–65.4)

0.049

Hemoglobin (g/l)

10.3 (9.4–11.3)

10.3 (9.1–11.4)

0.832

HBV infection (n,%)

3 (6.1 %)

4 (6.1 %)

1.000

CD4 + count (cells/µl)

390 (218–490)

336 (204–468)

0.655

HIV-RNA (logcopies/ml)

4.08 (3.26–4.68)

4.10 (3.28–4.60)

0.779

WHO stage (I/II/III–IV) (%)

77.6/10.2/12.2

77.3/19.7/3.0

0.423

ART duration in pregnancy (weeks)

10 (7.0–13.0)

10 (6.0–13.3)

1.000

ART regimen: (n, %)

   

 d4T- 3TC-NVP

 AZT-3TC-NVP

26 (53.1 %)

23 (46.9 %)

37 (56.1 %)

29 (43.9 %)

0.850

Unemployment (n, %)

32 (65.3 %)

38 (57.6 %)

0.444

Low educational level(no school or only primary) (n,%)

38 (77.6 %

36 (54.5 %)

0.018

No electricity at home (n, %)

41 (83.7 %)

49 (74.2 %)

0.260

Vaginal delivery (n, %)

47 (97.9)

64 (97)

1.000

Infants weight at birth (Kg)a

3.2 (2.8–3.5)

3.2 (2.6–3.5)

0.562

Male/female ratio (%)

49/51

45.5/54.5

0.850

HIV positive infants (n, %)b

1 (2.0)

1 (1.5)

1.000

CMV + infants at 12 monthsc

12/20 (60 %)

25/35 (71.4 %)

0.551

  1. Values are expressed as median (IQR) or percentage
  2. ART antiretroviral therapy, d4T stavudine, 3TC lamivudine, NVP nevirapine, AZT zidovudine
  3. aWeight measured within the first 15 days of birth
  4. bInfants acquiring HIV infection during the first year of life
  5. cNumber of infants = 55